Kombucha
1. Identity, Botanical Sources, and Common Forms
Kombucha (also written as kombucha tea or KT) is a fermented beverage produced by fermenting sweetened tea using a Symbiotic Culture of Bacteria and Yeast (SCOBY). Kombucha is a traditional beverage manufactured from fermenting tea (Camellia sinensis (L.) Kuntze) with a symbiotic culture of bacteria and yeast (SCOBY) in a sweet medium under aerobic conditions for several days. The SCOBY itself is the defining biological structure of the product: the SCOBY architecture is composed of a cellulose pellicle synthesized primarily by Komagataeibacter spp., forming a porous scaffold at the air–liquid interface that facilitates oxygen diffusion and supports microbial attachment and metabolite exchange.
The product is alternatively known by many regional and historical names. In Chinese, kombucha was historically known as hǎibǎo (lit. 'sea treasure'), derived from the SCOBY's resemblance to a jellyfish, and wèibǎo (lit. 'stomach treasure'), referring to its perceived medicinal benefits. Kombucha is usually fermented from sweetened tea using a SCOBY. The SCOBY is also known as tea fungus, cellulosic pellicle, or consortium.
Base Substrates and Tea Types
In general, black tea (post-fermented), oolong tea (semi-fermented), and green tea (non-fermented) are the main teas used in kombucha fermentation. Other tea varieties such as oolong tea, thyme, lemon balm, peppermint, rosemary, wheat grass, guava and oak leaves, fruit juices, milk, and laver have also been used to make kombucha. Both the composition of bioactive compounds and the resulting biological activities are dependent on the type of tea. Green tea is characterized by a higher content of polyphenols compared to black tea and oolong, and therefore stronger health-promoting properties resulting from the content of epigallocatechin-3-gallate (EGCG)—one of the strongest antioxidants in kombucha.
Common Forms and Preparations
Kombucha is most commonly available as a bottled, slightly effervescent liquid beverage. In small-scale and home brewing, kombucha is typically made in glass jars topped with fabric. Black or green tea leaves are steeped in hot water with sugar, then removed. When the sweetened tea has cooled, it is mixed with a bit of kombucha from a previous batch to make the liquid more acidic. A gelatinous mat of SCOBY is then added, and the brew is covered and left to ferment at room temperature for 7–30 days. The traditional beverage is prepared from fermentation of sweetened green or black teas, for 10 to 30 days under aerobic conditions, at 28–29 °C.
A "hard kombucha" variant also exists: hard kombucha has been allowed to ferment longer, producing a higher alcohol content than traditional kombucha; it typically contains around 4–7% alcohol by volume.
2. Traditional and Historical Use
Origins and Early History
The exact origin of kombucha is uncertain, though it likely originated in China and spread with tea along the Silk Road. It is widely brewed in parts of eastern Europe, particularly in rural Russia, and is common in China and Korea. Günther Frank, a German author who has conducted extensive research on kombucha, explains that although stories most often couple kombucha with East Asian cultures, most reports or allegations are simply anecdotal. Fermentation is at least 9,000 years old, and kombucha could be ancient, but reliable scientific documentation appears mostly in the early 1900s.
The most widely cited origin narrative places kombucha in China during the Qin Dynasty. One of the most well-known kombucha origin stories dates back to the Qin Dynasty (221 BCE) in China. Back then it was referred to as the "tea of immortality," "the elixir of life," or the "Godly Tsche (tea)." However, the precise origin cannot be confirmed.
Spread to Russia, Europe, and Beyond
According to a blog published by The Kombucha Center, the first definitive reports of the tea's use came from Russia and Ukraine in the late 1800s. During World War I, Russian and German POWs drank it. By the 1920s, kombucha was popular throughout Germany as a home and folk remedy. It was especially widespread in the Westphalian industrial region of Germany. Pharmacists sold it as "Mo-Gu" (the Chinese word for "mushroom") or "Fungojapon."
Traditional Purposes
In ancient societies, kombucha was used to promote longevity and vitality. It was believed to possess potent healing properties, addressing various ailments. Traditional use often centered on digestive health and emphasized its role as a therapeutic agent, consumed to restore balance and well-being within the body. It reflects kombucha's traditional reputation as a household digestive tonic.
3. Key Constituents and Active Compounds
Microbial Composition of the SCOBY
Kombucha fermentation relies on the synergistic action of microbial communities, such as yeast, acetic acid bacteria (AAB), and lactic acid bacteria (LAB). Depending on the region of the world, used raw materials, and the conditions of the fermentation, different genera, species, and strains of acetic acid bacteria, lactic acid bacteria, and yeasts are identified in SCOBY. The fermentation relies on the synergistic action of microorganisms such as Saccharomyces, Acetobacter, and Lactobacillus, and the composition and proportion of these microbial communities significantly influence the quality of the product. There are differences in the microbial composition of SCOBY starter cultures from different sources, which results in variations in the fermentation process and the quality of the final product.
Organic Acids
Kombucha contains organic acids including acetic, gluconic, glucuronic, lactic, and citric acids, which play a role in detoxification and product preservation. Acetic acid is the major organic acid. In addition to these primary organic acids, kombucha also contains other organic acids, such as citric acid, malic acid, tartaric acid, and succinic acid. The biosynthesis of these acids follows a defined pathway: during fermentation, sucrose is firstly hydrolyzed by yeast to glucose and fructose. The glucose produced is then metabolized into gluconic and glucuronic acids by the AAB, whereas fructose is metabolized by yeast to produce ethanol and carbon dioxide. The resulting alcohol is further metabolized by the AAB into acetic acid.
Polyphenols and Tea-Derived Compounds
Tea (C. sinensis) is a good source of antioxidants, and the main active components in tea are flavonoids such as catechin, epicatechin (EC), epigallocatechin (EGC), epicatechin-3-gallate (ECG), gallocatechin-3-gallate (GCG), epigallocatechin-3-gallate (EGCG), theaflavins, and thearubigins. Overall, 127 phenolic compounds (70.2% flavonoids, 18.3% phenolic acids, 8.4% other polyphenols, 2.3% lignans, and 0.8% stilbenes) have been identified in kombuchas. Phenolic derivatives including gallic, chlorogenic, and caffeic acids confer antioxidant and anti-inflammatory properties.
Vitamins and Minerals
Kombucha contains vitamins, amino acids, and bacteriocins. The vitamins in kombucha are mainly B vitamins (B1, B2, B6, and B12) and vitamin C. These vitamins are essential elements for the human body and offer health benefits, such as antioxidant properties, scurvy prevention, and immune support. Fermented kombucha teas contain many elements such as aluminium, calcium, iron, potassium, magnesium, sodium, phosphorus, and sulphur.
Other Bioactive Components
Besides the main metabolites of acetic acid and gluconic acid, kombucha also contains various tea compounds (e.g., theaflavin, thearubigin, polyphenols, and catechins), some B complex vitamins, ascorbic acid, carbon dioxide, trace amounts of alcohol, and essential minerals. The Lactobacillus in kombucha metabolizes and produces bacteriocins, which are antimicrobial peptides that effectively inhibit the proliferation of pathogenic and spoilage microorganisms. In this way, they, along with organic acids, contribute to the creation of a multi-layered antimicrobial barrier.
Alcohol Content
Naturally fermented kombucha contains 0 to 3% alcohol by volume (ABV). The alcohol content of commercial kombucha is typically very low, usually less than 0.5% by volume. Real-world testing has revealed variability: over half of tested samples from British Columbia processors contained elevated ethanol values exceeding 1% ABV (ranging from 0.14 to 3.33% ABV). Kombucha containing ethanol is concerning for pregnant women and young children, for whom low levels of ethanol consumption create adverse medical outcomes.
4. Established Mechanisms of Action
Antioxidant Mechanisms
Kombucha can both neutralize free radicals and support cellular defense mechanisms due to its polyphenols and organic acids. Research has explained the bioactivities in the human body, especially mechanisms of action in the intestine, through fundamental signaling pathways such as PIK3-AKT, MAPK, NFκB, PPARγ, and JAK-STAT. One study found that the antioxidant activity of kombucha changed according to the fermentation period and reached the highest level on the 7th day (93.8%), with a slight decrease subsequently observed as the duration increased, falling to 93.6% on the 11th day.
Antimicrobial Mechanisms
In vitro studies confirm the bactericidal and bacteriostatic properties of fermented kombucha beverages, with white and green tea beverages showing the highest antibacterial activity. The bacteria Staphylococcus aureus and yeast Candida albicans were the most sensitive to the effects of kombucha tea beverages. The presence of organic acids increases the acidity of kombucha, thereby inhibiting the growth of undesirable microorganisms.
Gut Microbiome Modulation
The rich composition of kombucha, including organic acids and phenolic compounds, provides potent antioxidant and anti-inflammatory properties that influence multiple molecular pathways across organs. Phenolic compounds exert prebiotic effects by modulating salivary and fecal microbiota, lowering fecal pH, stimulating beneficial bacteria, and increasing short-chain fatty acid (SCFA) production. This enhances gut barrier function and regulates metabolic, immune, and inflammatory responses. In the gut, organic acids improve motility by stimulating prostaglandin E2 secretion, enhancing peristalsis, and downregulating aquaporin-3.
Antidiabetic Mechanisms
Kombucha has been linked to improved glucose metabolism in preclinical studies, demonstrating enhanced pancreatic architecture, improved insulin secretion and function, and reduced glucose absorption in the small intestine. A compound called DSL, produced by Gluconacetobacter sp. during fermentation, inhibits the activity of beta-glucuronidase—an enzyme responsible for breaking glucuronide bonds in the intestinal lumen—which can release toxic aglycones. By inhibiting this enzyme, DSL contributes to intestinal and hepatic protection and also exhibits antioxidant properties that mitigate oxidative stress-related renal damage.
5. Scientific Evidence by Area of Use
5.1 Overall State of Human Evidence
Direct evidence supporting kombucha's benefits for human health is lacking. A systematic review published in 2003 found no clinical studies related to kombucha. Although kombucha has been associated with antioxidant, antimicrobial, probiotic, antidiabetic, and anticancer activities, strong scientific evidence in humans remains limited. Further clinical studies are needed to substantiate kombucha's health benefits in humans. Recent studies show controversial information about the effects of kombucha on health, often driven by different theories leading to the empirical use of the drink without standardization of quantity, forms, and preparation, which can cause harm to human health.
5.2 Blood Glucose and Diabetes
This is the area with the most direct, if still very preliminary, human clinical evidence.
In one pilot study, researchers tested kombucha as an anti-hyperglycemic therapeutic agent in human adult participants with type 2 diabetes (T2D). They observed that kombucha consumption by subjects with elevated blood glucose levels at baseline was associated with a significant reduction in fasting blood glucose that was not observed during consumption of a placebo beverage. To the authors' knowledge, this study was the first randomized controlled human trial in which the anti-diabetic effects of kombucha were assessed among diabetic participants.
Specifically regarding study design and outcomes: this clinical study aimed to explore the potential antihyperglycemic effects of kombucha in adults with type II diabetes mellitus (T2D). The study involved 12 participants aged 18 or older, following a prospective double-blinded crossover design. Participants were instructed to consume either kombucha or a placebo (240 ml/day) with dinner for four weeks. The results showed that kombucha reduced average fasting blood glucose levels compared to the baseline (164 mg/dl versus 116 mg/dl, p=0.035). Only seven participants who completed the entire study were included in the analysis of fasting blood glucose. The limited number of participants raises concerns about the robustness of the statistical calculations; thus, this study is considered a pilot trial.
A separate Australian randomized trial examined glycemic response in healthy adults: the study aimed to compare the glycemic and insulin responses of a high-carbohydrate meal paired with kombucha, soda water, or diet soft drink. Significant differences were found in a randomized trial with 11 healthy adults from Australia. Kombucha showed a lower change in plasma glucose from baseline to peak compared to soda water (p=0.003) and diet lemonade (p=0.008). The mean glycemic index values for kombucha were significantly lower than soda water (p=0.041) and diet drinks (p=0.050). However, caution is advised due to the small sample size.
An earlier, small non-controlled Indian study also found antidiabetic signals: in a small study involving 24 subjects with non-insulin dependent diabetes mellitus, daily intake of kombucha was associated with normalized blood sugar values. The totality of animal evidence is more consistent: there were five studies which stated that consumption of kombucha prepared with green tea significantly reduced blood glucose and lipid parameters, LDL cholesterol, total cholesterol and triglycerides, with increased HDL cholesterol. In addition, some studies found signs of weight reduction in the green tea and kombucha group and a potential antihyperglycemic effect relative to the control group. The mechanistic basis in animal studies involves phenolic compounds: black tea and green tea in isolation showed positive effects on glycemic control, but the effects were enhanced with the use of kombucha, as it contains higher antioxidant properties attributed to the fermentation process. The mechanism may be attributed to phenolic compounds present in kombucha, including caffeine derivatives, procyanidins and chlorogenic acid, which demonstrate improved insulin sensitivity and vascular endothelial function.
Evidence strength: Preliminary. The human evidence consists only of very small pilot and randomized crossover trials with major limitations (n=7–24, short duration, single-center). Animal and preclinical data are more abundant but cannot be directly extrapolated to humans.
5.3 Gut Microbiome and Digestive Health
An eight-week clinical trial explored the effects of a four-week kombucha supplement in healthy individuals consuming a Western diet, randomized into the kombucha (n=16) or control (n=8) group. Longitudinal stool and blood samples were collected to profile the human microbiome and inflammation markers. No significant changes in either biochemical parameters or levels of circulating markers of inflammation were observed across the entire cohort. However, paired analysis between baseline and end of intervention time points within the kombucha group revealed increases in fasting insulin and HOMA-IR in the kombucha group, whereas reductions in HDL cholesterol were associated with the control group.
While animal studies and in vitro research show promising results for kombucha's ability to improve gut health and microbiome diversity, human studies so far report only modest or limited effects.
Evidence strength: Weak to preliminary. Human trials in this area are few, small, and report mixed or non-significant results. Animal and in vitro data suggest plausible mechanisms but cannot substitute for human trial evidence.
5.4 Lipid Profile and Cardiovascular Risk
Animal evidence has been more robust than human data in this area. Wistar rats fed cholesterol-rich diets were given kombucha tea or green tea (5 mL/kg body weight per day, orally) for 16 weeks. Kombucha had higher phenolic compound content. The free radical scavenging activity of kombucha tea was higher than green tea. Compared with green tea, kombucha tea induced lowered serum levels of total cholesterol, triglycerides, VLDL-C, and LDL-C by 26, 27, 28, and 36%, respectively, and increased the serum level of HDL cholesterol.
Despite strong animal data showing 26–36% lipid reductions, human trials show no significant effects on cholesterol (P=0.373), triglycerides (P=0.958), or weight loss beyond caloric restriction.
Evidence strength: The lipid-lowering evidence is strong in animal models but entirely lacking in rigorous human clinical trials. Claims about cholesterol reduction in humans are not currently supported by clinical data.
5.5 Hepatoprotective Effects
Preclinical studies have shown anti-inflammatory, antioxidant, immunostimulatory, hypolipidemic, and hepatoprotective effects with limited toxicity. A rodent study specifically investigating nonalcoholic fatty liver disease found that kombucha tea ameliorated hepatic damage in mice by increasing hepatocyte survival and decreasing inflammation and fibrosis through the reduction of Hh (Hedgehog) activation. In addition, kombucha tea exerted protective action in hepatocytes from lipotoxin by suppressing lipid accumulation. These findings suggest that kombucha tea has the potential to prevent or treat NAFLD and NASH. When used as a hepatoprotective agent, kombucha has been reported to improve markers of oxidative stress and serum levels of liver enzymes in animal studies.
Evidence strength: Preclinical (animal/rodent) only. Kombucha demonstrates hepatoprotective properties in animal models through plausible biological mechanisms; whether these benefits translate to humans at typical consumption levels remains entirely unproven.
5.6 Antioxidant and Anti-inflammatory Effects
Phenolic compounds and other active substances in kombucha contribute to its significant antioxidant, antimicrobial, and immune-modulating properties. A greater diversity and abundance of phenolic compounds was detected in black tea kombucha, which resulted in a higher antioxidant capacity. However, the green tea kombucha was the only one that presented antibacterial activity against all bacteria tested and an increased antiproliferative activity against the cancer cell lines, which was attributed to the presence of catechins among the most abundant phenolic compounds. These findings are based on laboratory (in vitro) studies.
Evidence strength: Primarily in vitro and animal. No rigorous human clinical trials have confirmed antioxidant benefits as measured clinical endpoints.
5.7 Anticancer Activity
Cancer claims remain unproven: zero human trials exist for cancer prevention or treatment. All cancer-related observations come from cell-line (in vitro) experiments or animal studies, where kombucha and its constituent compounds have shown antiproliferative activity against certain cancer cell lines. No clinical human data support any anticancer indication. Therapeutic efficacy of kombucha, including delivery mechanisms of anticancer properties, has been reviewed only in preclinical contexts.
Evidence strength: In vitro and preclinical only. No human evidence.
6. Body Systems Associated with Kombucha
- Gastrointestinal system: Primary traditional target; associated with digestive tonic effects, gut microbiome modulation, and stool regularity.
- Metabolic/Endocrine system: Studied for blood glucose regulation and lipid profile effects.
- Hepatic (Liver) system: Hepatoprotective effects demonstrated in animal models of NAFLD/NASH; paradoxically also implicated in rare human hepatotoxicity case reports.
- Cardiovascular system: Investigated for hypolipidemic and antihypertensive effects; evidence is preclinical.
- Immune system: Vitamins in kombucha include B vitamins and vitamin C, which offer health benefits including immune support. Immunostimulatory effects shown in preclinical studies.
- Antimicrobial: Active against a range of pathogens in vitro, including Staphylococcus aureus and Candida albicans.
7. Dosage Forms and Reported Dosages
Kombucha is almost exclusively consumed as a liquid beverage. There is no established or standardized therapeutic dose. The following doses have been reported in specific studies:
- A double-blinded crossover pilot study in 12 participants with type 2 diabetes used 240 ml/day of kombucha with dinner for four weeks.
- An eight-week clinical trial used a four-week kombucha supplement in healthy individuals on a Western diet, randomized into kombucha (n=16) or control (n=8) groups.
- In a rat study examining lipid effects, the dose administered was 5 mL/kg body weight per day orally for 16 weeks.
- Clinical trials using 7–11 ounces (approximately 207–325 ml) daily reported no serious adverse events in their study populations.
Factors that substantially affect biological activities include tea type and its brewing parameters, the composition of the SCOBY, as well as the fermentation parameters. Kombucha fermentation is characterized by many unknowns, which result from different methods of tea extraction, diverse and often undefined compositions of microorganisms, as well as the lack of clearly defined effects of microorganisms on bioactive compounds. This variability means that no two batches of kombucha are guaranteed to be chemically equivalent, which is a major limitation for dosage standardization.
8. Safety Considerations and Known Interactions
Reported Adverse Events
Medical literature notes possible side effects including hepatotoxicity, digestive reactions, allergic reactions, and nephrotoxicity.
Lactic acidosis: Two women in Iowa in 1995 were admitted to hospital with fatal unexplained severe metabolic acidosis following consumption of kombucha tea, and a 22-year-old man with HIV developed acute renal failure and lactic acidosis rapidly after ingesting the tea. The mechanism by which kombucha tea is associated with these adverse effects is unclear, and the microbial composition of the culture and storage conditions may be contributory factors.
Hepatotoxicity: Kombucha-related adverse events have been described including allergic reactions, mild hepatotoxicity, and lactic acidosis. Kombucha tea consumption can produce side effects such as allergic reactions, nausea, vomiting, headache, and even jaundice. One patient with HIV developed severe lactic acidosis and renal failure after its consumption. Another patient developed a cholestatic hepatitis after kombucha consumption. In 1995, two patients from Iowa who consumed excessive amounts of kombucha developed an unexplained illness with lactic acidosis, leading to the death of one patient.
Dose relationship: Clinical trials using 7–11 ounces daily reported no serious adverse events. Case reports document liver toxicity at 48–64 or more ounces daily, including one case of greater than 95% hepatic necrosis.
Contamination Risks
Growing kombucha in unsanitary conditions has resulted in contaminated product. Lead poisoning has been associated with kombucha tea brewed in glazed ceramic pots. The Food and Drug Administration noted that kombucha might be produced under several conditions even in a domestic environment, thus contamination with pathogenic organisms such as Aspergillus is possible.
Drug Interactions
Kombucha tea is acidic. This may affect the bioavailability of drugs that depend on stomach pH levels for dissolution and absorption. Individuals taking medications whose absorption is pH-dependent should be aware of this interaction potential.
Alcohol Content Variability
Naturally fermented kombucha contains 0 to 3% alcohol by volume. However, kombucha containing ethanol is concerning for pregnant women and young children for whom low levels of ethanol consumption create adverse medical outcomes. In a British Columbia study, over half of tested samples from processors contained elevated ethanol values exceeding 1% ABV (0.14 to 3.33% ABV), suggesting that some processors did not have adequate control of excess alcohol during production.
Populations with Heightened Risk
Individuals with a suppressed immune system are at risk because contaminated kombucha beverages can activate immune responses. Individuals taking drugs that are sensitive to stomach pH levels should be aware that kombucha may reduce the absorption of these drugs.
References
- Antolak H, et al. "Kombucha Tea—A Double Power of Bioactive Compounds from Tea and Symbiotic Culture of Bacteria and Yeasts (SCOBY)." Antioxidants. 2021;10(10):1541. PMC
- Kapp JM, Sumner W. "Kombucha: a systematic review of the empirical evidence of human health benefit." Annals of Epidemiology. 2019;30:66–70. ScienceDirect
- Villarreal-Soto SA, et al. "Recent Progress in Chemical Composition, Production, and Pharmaceutical Effects of Kombucha Beverage: A Complementary and Alternative Medicine." PMC. 2020.
- Li X, et al. "A Comprehensive Evaluation of Microbial Synergistic Metabolic Mechanisms and Health Benefits in Kombucha Fermentation: A Review." Biology. 2025;14(8):952. PMC
- Kaczmarczyk K, et al. "Microbiological and Physicochemical Composition of Various Types of Homemade Kombucha Beverages Using Alternative Kinds of Sugars." PMC. 2022.
- "Kombucha Tea: A Functional Beverage and All its Aspects." PMC. 2025.
- "Shaping the Bioactive Properties of Kombucha Drinks by Using Raw Materials Alternative to Tea." PMC. 2026.
- Laavola M, et al. "Microbial Composition of SCOBY Starter Cultures Used by Commercial Kombucha Brewers in North America." PMC. 2021.
- "Kombucha: Production and Microbiological Research." PMC. 2022.
- "Microbiological and Physico-Chemical Characteristics of Black Tea Kombucha Fermented with a New Zealand Starter Culture." PMC. 2023.
- Mendelson C, et al. "Kombucha tea as an anti-hyperglycemic agent in humans with diabetes – a randomized controlled pilot investigation." Frontiers in Nutrition. 2023. PMC
- Tran T, et al. "Modulating the human gut microbiome and health markers through kombucha consumption: a controlled clinical study." Scientific Reports. 2024.
- "Kombucha Beverages Produced from Fruits, Vegetables, and Plants: A Review on Their Pharmacological Activities and Health Benefits." PMC. 2023.
- Lee C, et al. "Hepatoprotective Effect of Kombucha Tea in Rodent Model of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis." International Journal of Molecular Sciences. 2019. PMC
- Aloulou A, et al. "Protective effect of kombucha on rats fed a hypercholesterolemic diet is mediated by its antioxidant activity." PubMed. 2012.
- "Benefits of Kombucha Consumption: A Systematic Review of Clinical Trials Focused on Microbiota and Metabolic Health." ResearchGate. 2025.
- "Kombucha-Induced Massive Hepatic Necrosis: A Case Report and a Review of Literature." Gastro Hep Advances. 2022.
- Holbourn A, Hurdman J. "Kombucha: is a cup of tea good for you?" BMJ Case Reports. 2017. PMC
- Memorial Sloan Kettering Cancer Center. "Kombucha." Integrative Medicine. 2021.
- "A Review of side effects of Kombucha." Clinical Surgery Group. 2023.
- "Ethanol Concentration of Kombucha Teas in British Columbia, Canada." Journal of Food Protection. 2022. ScienceDirect
- "Assessing Kombucha: A Systematic Review of Health Effects in Humans." 2024.
- Smithsonian Center for Folklife and Cultural Heritage. "The Cloudy Origins of Kombucha." 2019.
- Britannica. "Kombucha | Description, History, SCOBY, & Nutrition." 2024.
- Wikipedia. "Kombucha." 2024.
- "A Comprehensive Review of Kombucha Fermentation and Probiotic Functional Mechanisms." Probiotics and Antimicrobial Proteins. 2026. Springer Nature.
- ClinicalTrials.gov. "Kombucha in Overweight and Obese: Live Vs. Pasteurized Effects on Microbiota, Metabolism, and Liver Function." NCT06759324.
Volver